tetano
Editor, Senior Moderator
Influenza Other Respi Viruses. 2011 Dec 22. doi: 10.1111/j.1750-2659.2011.00321.x. [Epub ahead of print]
Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1.
Vela EM, Buccellato MA, Tordoff K, Stark G, Bigger JE.
Source
Battelle, Columbus, OH, USA.
Abstract
Please cite this paper as: Vela et al. (2011) Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2011.00321.x Background In 1997, highly pathogenic avian influenza (HPAI) viruses caused outbreaks of disease in domestic poultry markets in Hong Kong. The virus has also been detected in infected poultry in Europe and Africa. Objective The objective of this study was to determine the efficacy of a heterologous vaccine administered with and without the aluminum hydroxide adjuvant in ferrets challenged with HPAI (A/Vietnam/1203/04). Methods Animals in four of the five groups were vaccinated twice 21 days apart, with two doses of a heterologous monovalent subvirion vaccine with or without an aluminum hydroxide adjuvant and challenged with a lethal target dose of A/Vietnam/1203/04. Results All animals vaccinated with the heterologous vaccine in combination with the aluminum hydroxide adjuvant survived a lethal challenge of A/Vietnam/1203/04. Four of the eight animals vaccinated with 30 μg of the vaccine without the adjuvant survived, while two of the eight animals vaccinated with 15 μg of the vaccine without the adjuvant survived. None of the unvaccinated control animals survived challenge. Additionally, changes in virus recovered from nasal washes and post-mortem tissues and serology suggest vaccine efficacy. Conclusions Altogether, the data suggest that the heterologous vaccine in combination with the aluminum hydroxide adjuvant offers maximum protection against challenge with A/Vietnam/1203/04 when compared to the unvaccinated control animals or animals vaccinated without any adjuvant.
? 2011 Blackwell Publishing Ltd.
PMID:
22192389
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22192389
Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1.
Vela EM, Buccellato MA, Tordoff K, Stark G, Bigger JE.
Source
Battelle, Columbus, OH, USA.
Abstract
Please cite this paper as: Vela et al. (2011) Efficacy of a heterologous vaccine and adjuvant in ferrets challenged with influenza virus H5N1. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2011.00321.x Background In 1997, highly pathogenic avian influenza (HPAI) viruses caused outbreaks of disease in domestic poultry markets in Hong Kong. The virus has also been detected in infected poultry in Europe and Africa. Objective The objective of this study was to determine the efficacy of a heterologous vaccine administered with and without the aluminum hydroxide adjuvant in ferrets challenged with HPAI (A/Vietnam/1203/04). Methods Animals in four of the five groups were vaccinated twice 21 days apart, with two doses of a heterologous monovalent subvirion vaccine with or without an aluminum hydroxide adjuvant and challenged with a lethal target dose of A/Vietnam/1203/04. Results All animals vaccinated with the heterologous vaccine in combination with the aluminum hydroxide adjuvant survived a lethal challenge of A/Vietnam/1203/04. Four of the eight animals vaccinated with 30 μg of the vaccine without the adjuvant survived, while two of the eight animals vaccinated with 15 μg of the vaccine without the adjuvant survived. None of the unvaccinated control animals survived challenge. Additionally, changes in virus recovered from nasal washes and post-mortem tissues and serology suggest vaccine efficacy. Conclusions Altogether, the data suggest that the heterologous vaccine in combination with the aluminum hydroxide adjuvant offers maximum protection against challenge with A/Vietnam/1203/04 when compared to the unvaccinated control animals or animals vaccinated without any adjuvant.
? 2011 Blackwell Publishing Ltd.
PMID:
22192389
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22192389